<DOC>
	<DOCNO>NCT01064973</DOCNO>
	<brief_summary>Study 22003 , `` An Open-Label , Flexible-Dose Evaluation Safety Tolerability STX209 Treatment Irritability Subjects With Autism Spectrum Disorders ( ASD ) '' currently evaluate efficacy STX209 ( R-baclofen ) management typical problem behavior , irritability aggression , subject ASD . This study ( 22007 ) enter subject complete Study 22003 long-term , open-label study.The open-label extension protocol provide necessary data long-term safety tolerability STX209 among subject ASD receive treatment condition closely reflective general medical care .</brief_summary>
	<brief_title>An Open Label Extension Study STX209 Subjects With Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Have complete schedule visit protocol 22003 show adequately follow protocol , sufficient medical justification continue openlabel treatment STX209 , assess principal investigator Subjects medical condition might interfere conduct study , confound interpretation study result , endanger wellbeing . The occurrence continuation adverse event condition study 22003 , opinion Investigator , exclude subject participate openlabel extension</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>autism</keyword>
</DOC>